The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Theraclion S.A.S., set up in 2004 as a spin-off from French EDAP-Technomed, is the only medtech company in the world developing a High Intensity Focused Ultrasound technology for the treatment of primary and secondary hyperparathyroidism and thyroid nodules. Theraclion offers the first simple, non-invasive, lower-cost, outpatient-based alternative for treating these conditions. The HIFU treatment is performed under analgesia and takes around 30 minutes.
Primary hyperparathyroidism has a potential market of over €300 million and secondary hyperparathyroidism corresponds to a potential of 1.5bn€ easily accessible patients on dialysis. The device created by Theraclion, the TH-One is CE marked and is being launched on the EU market.
Truffle Capital is Theraclion’s majority shareholder.
Truffle Capital board members: Dr. Philippe Pouletty